Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 12/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716704 | 1.00 | KDM5B (0.57) | KDM5BMAPTTP53SMN1; SMN2CCNE2 | |
| SCHEMBL4714960 | 0.85 | KDM5B (0.53) | KDM5BMAPTTP53SMN1; SMN2 | |
| SCHEMBL4714965 | 0.85 | KDM5B (0.53) | KDM5BMAPTTP53SMN1; SMN2 | |
| SCHEMBL4717904 | 0.78 | KDM5B (0.49) | KDM5BMAPTTP53SMN1; SMN2 | |
| SCHEMBL6644372 | 0.77 | BRD4 (0.58) | MAPTCDK2CYP2A6ADRA1B | |
| SCHEMBL4715412 | 0.75 | KDM5B (0.40) | KDM5BMAPTTP53SMN1; SMN2 | |
| SCHEMBL4715415 | 0.75 | KDM5B (0.40) | KDM5BMAPTTP53SMN1; SMN2 | |
| SCHEMBL4718874 | 0.74 | KDM5B (0.56) | KDM5BMAPTTP53SMN1; SMN2 | |
| SCHEMBL4717295 | 0.74 | KDM5B (0.49) | KDM5BMAPTTP53SMN1; SMN2CCNE2 | |
| SCHEMBL4717292 | 0.74 | KDM5B (0.49) | KDM5BMAPTTP53SMN1; SMN2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218383-B1 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-11-05 | — | — | EP | claimed |
| US-6936631-B2 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2005-08-30 | — | — | US | claimed |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| JP-2003511456-A | — | — | 2003-03-25 | — | — | JP | claimed |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2002-12-05 | — | — | US | claimed |
| EP-1218383-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001027118-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| EP-1218383-B1 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-11-05 | — | — | EP | disclosed |
| US-6936631-B2 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| US-6657064-B2 | For use as analgesics | GRUENENTHAL GMBH (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| EP-1218383-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027118-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | ACHE, P2RX5, CNR1 | KDM5B 968/4885MAPT 3783/4885TP53 4215/4885 |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | ACHE, P2RX5, CNR1 | KDM5B 968/4885MAPT 3783/4885TP53 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.